ICU Medical CEO leaves as sale rumors subside
This article was originally published in Clinica
Executive Summary
George Lopez has stepped down as president and CEO of ICU Medical, for health reasons, after 24 years at the helm and 27 years with the company. Dr Lopez will remain chairman and an employee of the firm’s R&D department. ICU has appointed Steven Riggs, currently vice-president of operations, as acting CEO while it looks for a full-time replacement. The news coincides with media reports that ICU has halted its sale process after failing to find a buyer. Rumors that it was up for sale surfaced in August, with private equity firm GTCR touted as a potential suitor (www.clinica.co.uk, 5 August 2013). ICU’s share price dropped 6% to close $63.66 on 24 October, the day the speculation that it was no longer an acquisition target emerged.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.